Nashik, May 12: “With the recent UK-India Free Trade Agreement (FTA) reducing import tariffs on advanced medical equipment, we indeed foresee significant positive implications for healthcare providers like HCG Manavata Cancer Centre.

The lowered import costs on high-end medical technologies — including robotic surgical systems and precision oncology equipment — have the potential to directly benefit both providers and patients. At HCG Manavata, we are committed to delivering cutting-edge cancer care, and reduced capital costs for advanced surgical technologies will allow us to enhance access to sophisticated procedures such as robotic-assisted surgeries.

Over time, as these technologies become more accessible and costs decline, we anticipate a narrowing gap between the pricing of robotic-assisted surgeries and conventional cancer surgeries. This will make advanced cancer treatments more affordable and accessible to a broader segment of patients, particularly in tier-II and tier-III cities, where affordability has historically been a barrier.

Moreover, this development is poised to elevate the standard of cancer care in India. Greater availability of advanced equipment will enable more precise, minimally invasive surgeries with shorter recovery times and better outcomes — aligning Indian cancer care more closely with global best practices.

We view this as an opportunity not just to upgrade technology but also to expand equitable access to high-quality cancer care, furthering our mission of bringing comprehensive oncology services to every patient in need,” says Prof Dr Raj Nagarkar, Chief of Surgical Oncology & Robotic Services & Managing Director, HCG Manavata Cancer Centre (HCGMCC) & Hospitals.

About HCG Manavata Cancer Centre (HCGMCC): -

Established in 2007 by Dr Raj Nagarkar, HCGMCC – Nashik is Central India's first NABH-accredited facility. With over 50 consultant oncologists, 900 staff members and a 275-bed capacity, HCGMCC is a leading institution, offering holistic cancer treatment. Specializing in surgical, radiation and medical oncology, the centre has conducted 65,000 surgeries, including 1,100 plus robotic-assisted procedures. Patient-centric and multidisciplinary, HCGMCC recommends treatments to individual needs. Beyond clinical excellence, the centre’s financial aid programs underscore its commitment to accessibility and community well-being, redefining cancer care in the pursuit of a cancer-free future.